Skip to main content
. 2016 Oct 17;10:232. doi: 10.3389/fncel.2016.00232

Figure 1.

Figure 1

Effect of the Transient receptor potential vanilloid 4 (TRPV4) agonist GSK1016790A on methane dicarboxylic aldehyde (MDA) and nitric oxide (NO) content. (A,B) The MDA content in the hippocampus was increased in a dose-dependent manner by the application of the TRPV4 agonist GSK1016790A (0.1–5 μM/mouse), and the EC50 and n values of the dose-response curve were 0.63 ± 0.14 μM/mouse and 1.40, respectively. (C,D) The NO content in the hippocampus was increased by injection of GSK1016790A (0.1–5 μM/mouse) in a dose-dependent manner, and the EC50 and n values of the dose-response curve were 0.69 ± 0.04 μM/mouse and 1.33, respectively. **P < 0.01 vs. control.